ImmunityBio, Inc.
News
18,704 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Purchased by CIBC Asset Management Inc
Ticker Report CIBC Asset Management Inc acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The...\n more…
ImmunityBio Presents Positive Long-Term Overall Survival Datain Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA and Checkpoint Immunotherap
Business Wire Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years...\n more…
Short Interest in ImmunityBio, Inc. (NASDAQ:IBRX) Grows By 5.2%
Ticker Report ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 49,180,000 shares, a growth of...\n more…
ImmunityBio (NASDAQ:IBRX) Trading Down 6% on Analyst Downgrade
Ticker Report ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) traded down 6% during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $6.00 to $4.75. Piper Sandler...\n more…
ImmunityBio (NASDAQ:IBRX) PT Lowered to $4.75
Ticker Report ImmunityBio (NASDAQ:IBRX - Get Free Report) had its target price lowered by equities researchers at Piper Sandler from $6.00 to $4.75 in a research report issued to clients and investors on Monday...\n more…
ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious
SeekingAlpha ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious...\n more…